AIM Therapeutics is an early stage pharmaceutical company focused on developing breakthrough medical treatments for inflammatory and immune disorders including asthma, spinal cord injury, and restenosis.
Our mission is to provide hope and create a better future for people suffering from debilitating inflammatory diseases. We have an unrelenting passion for what we do, and we are proud of the progress that we’re making. We hope that while clicking through our web site you sense the excitement and pride with which we approach our work. We invite you to visit our web site frequently to follow our developments, and we encourage you to contact us directly with any ideas or questions you may have.
The AIM Therapeutics Annual General Meeting will be held on Tuesday, January 27th, 2009 at 10:30 a.m. at BLG Toronto, Scotia Plaza, 40 King Street West, Toronto, Ontario, M5H 3Y4. Financial statements and meeting materials will be sent to all shareholders the week of January 12th, 2009.
I am pleased to report that AIM Therapeutics has continued to successfully advance its programs and activities as planned.